ConductScience.org, home

Paper39014279

Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review.

Mansilla-Polo M and 1 other. Dermatol Ther (Heidelb), 2024. Cited by 35 papers, by iCite.

Cite this record

ConductScience Library. Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review. Papers, record 39014279. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39014279

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review.
PubMed
Journal
Dermatol Ther (Heidelb)
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
35
iCite
Relative citation ratio, by iCite
6.03, provisional
iCite
Revised in PubMed
2024-09-27
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mansilla-Polo MMiguel
2Morgado-Carrasco DDanielhttps://orcid.org/0000-0002-4704-6132

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References126

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130581616Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: Usefulness of administrative data.J Adv Res2019https://conductscience.org/library/papers/30581616PubMed
233419176Chronic Inflammatory Diseases, Anti-Inflammatory Agents and Their Delivery Nanosystems.Pharmaceutics2021https://conductscience.org/library/papers/33419176PubMed
329908671New-generation JAK inhibitors: how selective can they be?Lancet2018https://conductscience.org/library/papers/29908671PubMed
437331618Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders.Actas Dermosifiliogr2023https://conductscience.org/library/papers/37331618PubMed
537596779JAK inhibitors and black box warnings: what is the future for JAK inhibitors?Expert Rev Clin Immunol2023https://conductscience.org/library/papers/37596779PubMed
622532633Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.Ann Rheum Dis2013https://conductscience.org/library/papers/22532633PubMed
723240738Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease.Aliment Pharmacol Ther2013https://conductscience.org/library/papers/23240738PubMed
823462785Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.JAMA2013https://conductscience.org/library/papers/23462785PubMed
924462626Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.Clin Gastroenterol Hepatol2014https://conductscience.org/library/papers/24462626PubMed
1024414744Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0.Rheumatol Int2014https://conductscience.org/library/papers/24414744PubMed
1125557144Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.Int J Rheum Dis2015https://conductscience.org/library/papers/25557144PubMed
1226472414The Risk of Tuberculosis in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor-α Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies.J Rheumatol2015https://conductscience.org/library/papers/26472414PubMed
1325970800Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).JAMA Dermatol2015https://conductscience.org/library/papers/25970800PubMed
1428160418Comparison of the risk of infections in different anti-TNF agents: a meta-analysis.Int J Rheum Dis2017https://conductscience.org/library/papers/28160418PubMed
1528336735Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials.BMJ Open2017https://conductscience.org/library/papers/28336735PubMed
1629054603Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).J Invest Dermatol2018https://conductscience.org/library/papers/29054603PubMed
1728717941The Comparative Safety of TNF Inhibitors in Ankylosing Spondylitis-a Meta-Analysis Update of 14 Randomized Controlled Trials.Clin Rev Allergy Immunol2018https://conductscience.org/library/papers/28717941PubMed
1829655835Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.Gastroenterology2018https://conductscience.org/library/papers/29655835PubMed
1930763469Relative risk of tuberculosis in patients with rheumatic diseases managed with anti-tumour necrosis factor-alpha therapy: A nationwide cohort study.J Clin Pharm Ther2019https://conductscience.org/library/papers/30763469PubMed
2031799498Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics.BMC Rheumatol2019https://conductscience.org/library/papers/31799498PubMed

See all 126 referencesDownload CSV of references

Cited by27

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 35 citations.

PMIDTitleJournalYearIn PapersSource
42930036Antibody-Related Mechanisms in Ocular Diseases: Autoimmunity, Malignancy, and Therapeutic Targeting.Antibodies (Basel)2026https://conductscience.org/library/papers/42930036PubMed
42663861
Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials.
Dermatol Ther (Heidelb)2026https://conductscience.org/library/papers/42663861PubMed
42566613Rare primary bone tuberculosis associated with ruxolitinib therapy: A case report and literature review.Medicine (Baltimore)2026https://conductscience.org/library/papers/42566613PubMed
42459641Efficacy and safety of dupilumab following discontinuation of JAK inhibitors in patients with moderate-to-severe atopic dermatitis: a single-center retrospective study.Front Immunol2026https://conductscience.org/library/papers/42459641PubMed
42397402[Vaccination of immunocompromised individuals: Expert opinion - update 2026].Wien Klin Wochenschr2026https://conductscience.org/library/papers/42397402PubMed
42312036Global, regional, and national burden of bone and joint infections, 1990-2021: a comprehensive analysis of trends, pathogens, and antimicrobial resistance.Front Cell Infect Microbiol2026https://conductscience.org/library/papers/42312036PubMed
42176150PCR-confirmed severe geographic HSV-1 keratitis associated with systemic JAK inhibitor therapy.J Ophthalmic Inflamm Infect2026https://conductscience.org/library/papers/42176150PubMed
42169865Prescription Pattern and Safety of Biologics in Autoimmune Rheumatologic Diseases in Tertiary Care Hospital of Bihar.Clin Med Insights Arthritis Musculoskelet Disord2026https://conductscience.org/library/papers/42169865PubMed
42133200Dermatologic Toxicities Induced by JAK Inhibitors.Am J Clin Dermatol2026https://conductscience.org/library/papers/42133200PubMed
42047749[Biologics and infections: understand and recognize].Dermatologie (Heidelb)2026https://conductscience.org/library/papers/42047749PubMed
41978829Post-translational Modifications in Proteins: Prediction Methods, Biological Functions, and Diseases.MedComm (2020)2026https://conductscience.org/library/papers/41978829PubMed
41526852From infection to infarction: cytomegalovirus retinitis complicated by retinal ischemia and vitreous hemorrhage in the setting of JAK inhibition - a case report.BMC Ophthalmol2026https://conductscience.org/library/papers/41526852PubMed
41418047Trends in mortality, pathogen distribution, and antimicrobial resistance of peritoneal and intra-abdominal infections from 1990 to 2021: a cross-sectional analysis of the MICROBE database.Int J Surg2025https://conductscience.org/library/papers/41418047PubMed
41393140Therapeutic potential of peptidomimetics of suppressors of cytokine signaling (SOCS) proteins in rheumatic disorders.Front Med (Lausanne)2025https://conductscience.org/library/papers/41393140PubMed
41373641From Pathways to Patients in Atopic Dermatitis: Advanced Systemic Therapies.Int J Mol Sci2025https://conductscience.org/library/papers/41373641PubMed
40949126Ruxolitinib alleviates DSS-induced acute ulcerative colitis by inhibiting STAT1 phosphorylation and reducing MDSC infiltration.Front Pharmacol2025https://conductscience.org/library/papers/40949126PubMed
40949078Janus Kinase Inhibitors As Emerging Therapy in the Treatment of Psoriatic Arthritis: A Narrative Review of Efficacy, Safety, and Future Perspective.Cureus2025https://conductscience.org/library/papers/40949078PubMed
40860887Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis.Front Pharmacol2025https://conductscience.org/library/papers/40860887PubMed
40725743Anti-Inflammatory Therapies for Atopic Dermatitis: A New Era in Targeted Treatment.J Clin Med2025https://conductscience.org/library/papers/40725743PubMed
40717929Successful Treatment of Recalcitrant Eosinophilic Pustular Folliculitis with Dupilumab.Sultan Qaboos Univ Med J2025https://conductscience.org/library/papers/40717929PubMed

See all 27 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
IL1A3552PubTator's text mininghttps://conductscience.org/library/genes/3552NCBI Gene
IL23A51561PubTator's text mininghttps://conductscience.org/library/genes/51561NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39014279

GET https://conductscience.org/api/papers/v1/39014279/references?page=2